Livzon Pharmaceutical Group Inc. (FRA:LP6)

Market Cap	3.42B -5.6%
Revenue (ttm)	1.46B +1.8%
Net Income	246.37M -1.8%
EPS	0.28 +1.2%
Shares Out	n/a
PE Ratio	13.88
Forward PE	12.03
Dividend	0.13 (4.58%)
Ex-Dividend Date	Jun 13, 2025

Volume	n/a
Average Volume	21
Open	2.880
Previous Close	2.800
Day's Range	2.880 - 2.880
52-Week Range	2.760 - 4.300
Beta	n/a
RSI	45.39
Earnings Date	Mar 24, 2026

About FRA:LP6

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neuro...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 8,878
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LP6

Financial Performance

In 2025, FRA:LP6's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.

Financial numbers in CNY